Summary

Eligibility
for people ages up to 18 years (full criteria)
Location
at Oakland, California and other locations
Dates
study started
completion around
Principal Investigator
by Rohini Jain
Headshot of Rohini Jain
Rohini Jain

Description

Summary

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).

Details

Keywords

Langerhans Cell Histiocytosis, Langerhans-Cell Histiocytosis, Histiocytosis, Cytarabine, Prednisone, Indomethacin, Methotrexate, Mercaptopurine, Vinblastine, Cladribine, Immunoglobulins, Intravenous Immunoglobulins, gamma-Globulins, Rho(D) Immune Globulin, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin

Eligibility

Locations

  • UCSF Benioff Children's Hospital of Oakland completed
    Oakland California 94609 United States
  • UCSF Helen Diller Family Cancer Center accepting new patients
    San Francisco California 94158-0106 United States
  • Valley Children's Healthcare accepting new patients
    Madera California 93636 United States

Lead Scientist at UCSF

  • Rohini Jain
    Dr. Rohini Jain is a pediatric hematologist-oncologist who cares for patients with a variety of childhood cancers, while also providing support for their families. She has special interests in lymphoma and histiocytic disorders. Her research focuses on health disparities and medical education.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
North American Consortium for Histiocytosis
ID
NCT02205762
Phase
Phase 2/3 Langerhans Cell Histiocytosis Research Study
Study Type
Interventional
Participants
Expecting 1400 study participants
Last Updated